Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.02.9099.4750
Address
Level 1 3-5 George Street Leichardt, New South Wales (NSW) 2040
Description
Atomo Diagnostics Ltd. engages in manufacture, research, development, and design of in-vitro medical devices for blood-based rapid diagnostic testing (RDT) for professional use and self-testing. It offers its products through the AtomoRapid range of RDT platforms. The company was founded by John Kelly in 2010 and is headquartered in Leichhardt, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.01 - 0.03
Trade Value (12mth)
AU$1,575.00
1 week
0%
1 month
-17.65%
YTD
-28.21%
1 year
-50%
All time high
0.63
EPS 3 yr Growth
0.90%
EBITDA Margin
-134.60%
Operating Cashflow
-$5m
Free Cash Flow Return
-37.60%
ROIC
-54.90%
Interest Coverage
-577.90
Quick Ratio
4.80
Shares on Issue (Fully Dilluted)
639m
HALO Sector
Healthcare
Next Company Report Date
29-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
10 July 25 |
Becoming a substantial holder
×
Becoming a substantial holder |
09 July 25 |
Application for quotation of securities - AT1
×
Application for quotation of securities - AT1 |
09 July 25 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
04 July 25 |
Application for quotation of securities - AT1
×
Application for quotation of securities - AT1 |
04 July 25 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
04 July 25 |
Change of Director's Interest Notice x 3
×
Change of Director's Interest Notice x 3 |
27 June 25 |
Share Purchase Plan Results & Tranche 2 Placement Approved
×
Share Purchase Plan Results & Tranche 2 Placement Approved |
27 June 25 |
Application for quotation of securities - AT1
×
Application for quotation of securities - AT1 |
27 June 25 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
23 June 25 |
Results of Extraordinary General Meeting
×
Results of Extraordinary General Meeting |
27 May 25 |
Atomo secures Australian order for supply of HIV Self-Tests
×
Atomo secures Australian order for supply of HIV Self-Tests |
23 May 25 |
Atomo Appoints Interim Chair
×
Atomo Appoints Interim Chair |
23 May 25 |
Notice of Extraordinary General Meeting
×
Notice of Extraordinary General Meeting |
20 May 25 |
Share Purchase Plan Prospectus
×
Share Purchase Plan Prospectus |
20 May 25 |
Target Market Determination
×
Target Market Determination |
20 May 25 |
Share Purchase Plan Offer Opens
×
Share Purchase Plan Offer Opens |
09 May 25 |
Change in substantial holding
×
Change in substantial holding |
05 May 25 |
Update - Proposed issue of securities - AT1
×
Update - Proposed issue of securities - AT1 |
05 May 25 |
Application for quotation of securities - AT1
×
Application for quotation of securities - AT1 |
05 May 25 |
Notification regarding unquoted securities - AT1
×
Notification regarding unquoted securities - AT1 |
05 May 25 |
Notification of cessation of securities - AT1
×
Notification of cessation of securities - AT1 |
05 May 25 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
05 May 25 |
Initial Director's Interest Notice x 2
×
Initial Director's Interest Notice x 2 |
05 May 25 |
Final Director's Interest Notice x 3
×
Final Director's Interest Notice x 3 |
24 April 25 |
Atomo completes Capital Raise and undertakes Restructure
×
Atomo completes Capital Raise and undertakes Restructure |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.